Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases

NCT03366337 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT03366337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03366337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
December 26, 2017
Completion date
January 29, 2019
Enrollment
103 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

autosomal dominant polycystic kidney, ckd associated with type 1 diabetes, focal segmental glomerulosclerosis, iga nephropathy